|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, June 23, 2017 ) Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) targeted therapeutics development and features dormant and discontinued projects.
Publisher's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
For more information about this report at http://www.reportsweb.com/programmed-cell-death-1-ligand-1-pd-l1-or-b7-homolog-1-or-cd274-pipeline-review-h2-2016
Report Scope
- The report provides a snapshot of the global therapeutic landscape for Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274)
- The report reviews Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) targeted therapeutics and enlists all their major and minor projects
- The report assesses Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) targeted therapeutics
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001492663/sample
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Key Company profiles
Abeome Corporation
Alnylam Pharmaceuticals, Inc.
AlphaMab Co., Ltd
AstraZeneca Plc
Aurigene Discovery Technologies Limited
Avacta Group Plc
BeiGene, Ltd.
Bristol-Myers Squibb Company
CBT Pharmaceuticals Inc
CytomX Therapeutics, Inc.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Genosco
ImmunoCellular Therapeutics, Ltd.
Immunocore Limited
IO Biotech ApS
Kadmon Corporation, LLC
Kymab Limited
MedImmune, LLC
Merck KGaA
Merus NV
Novartis AG
PsiOxus Therapeutics Limited
Regeneron Pharmaceuticals Inc
Shanghai Henlius Biotech Co., Ltd.
Sorrento Therapeutics, Inc.
Sutro Biopharma, Inc.
Theravectys SA
Tikcro Technologies, Ltd.
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001492663/discount
List of Tables
Number of Products under Development for, H2 2016 14
Number of Products under Development by Therapy Area, H2 2016 15
Number of Products under Development by Indication, H2 2016 16
Comparative Analysis by Late Stage Development, H2 2016 19
Comparative Analysis by Early Stage Products, H2 2016 20
Number of Products under Development by Companies, H2 2016 21
Number of Products under Development by Companies, H2 2016 (Contd..1) 22
Products under Development by Companies, H2 2016 23
Products under Development by Companies, H2 2016 (Contd..1) 24
Products under Development by Companies, H2 2016 (Contd..2) 25
Products under Development by Companies, H2 2016 (Contd..3) 26
Products under Development by Companies, H2 2016 (Contd..4) 27
Products under Development by Companies, H2 2016 (Contd..5) 28
Products under Development by Companies, H2 2016 (Contd..6) 29
Products under Development by Companies, H2 2016 (Contd..7) 30
Products under Development by Companies, H2 2016 (Contd..8) 31
Products under Development by Companies, H2 2016 (Contd..9) 32
Products under Development by Companies, H2 2016 (Contd..10) 33
Number of Products under Investigation by Universities/Institutes, H2 2016 34
Products under Investigation by Universities/Institutes, H2 2016 35
Assessment by Monotherapy/Combination Products, H2 2016 36
Number of Products by Stage and Mechanism of Action, H2 2016 37
Number of Products by Stage and Route of Administration, H2 2016 39
Number of Products by Stage and Molecule Type, H2 2016 41
Pipeline by Abeome Corporation, H2 2016 42
Pipeline by Alnylam Pharmaceuticals, Inc., H2 2016 43
Pipeline by AlphaMab Co., Ltd, H2 2016 44
Pipeline by AstraZeneca Plc, H2 2016 45
Pipeline by Aurigene Discovery Technologies Limited, H2 2016 46
Pipeline by Avacta Group Plc, H2 2016 47
Pipeline by BeiGene, Ltd., H2 2016 48
Pipeline by Bristol-Myers Squibb Company, H2 2016 49
Pipeline by CBT Pharmaceuticals Inc, H2 2016 50
Pipeline by CytomX Therapeutics, Inc., H2 2016 51
Pipeline by Eli Lilly and Company, H2 2016 52
Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 53
Pipeline by Genosco, H2 2016 55
Pipeline by ImmunoCellular Therapeutics, Ltd., H2 2016 56
Pipeline by Immunocore Limited, H2 2016 57
Pipeline by IO Biotech ApS, H2 2016 58
Pipeline by Kadmon Corporation, LLC, H2 2016 59
Pipeline by Kymab Limited, H2 2016 60
Pipeline by MedImmune, LLC, H2 2016 61
Pipeline by Merck KGaA, H2 2016 63
Pipeline by Merus NV, H2 2016 64
Pipeline by Novartis AG, H2 2016 65
Pipeline by PsiOxus Therapeutics Limited, H2 2016 66
Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 67
Pipeline by Shanghai Henlius Biotech Co., Ltd., H2 2016 68
Pipeline by Sorrento Therapeutics, Inc., H2 2016 69
Pipeline by Sutro Biopharma, Inc., H2 2016 70
Pipeline by Theravectys SA, H2 2016 71
Pipeline by Tikcro Technologies, Ltd., H2 2016 72
Dormant Projects, H2 2016 167
Discontinued Products, H2 2016 168
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001492663/buy/3500
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
